| Record ID | ia:whoexpertcommitt0000whoe_y5p9 |
| Source | Internet Archive |
| Download MARC XML | https://archive.org/download/whoexpertcommitt0000whoe_y5p9/whoexpertcommitt0000whoe_y5p9_marc.xml |
| Download MARC binary | https://www.archive.org/download/whoexpertcommitt0000whoe_y5p9/whoexpertcommitt0000whoe_y5p9_meta.mrc |
LEADER: 03633cam 2200613Ia 4500
001 ocn839866006
003 OCoLC
005 20211126072842.0
008 130418s2012 sz b i000 0 eng
040 $aNz$beng$cNZWMM$dCUX$dTPH$dPCP$dNUI$dUKMGB$dYDX$dYDXCP$dUPM$dOCLCF$dOCLCQ$dBDX$dOTZ$dOCLCA$dNJR$dQE2$dOCLCQ
016 7 $a016324214$2Uk
019 $a840430634$a880216977$a980553107$a1055594189$a1089783751
020 $a9789241209731$q(pbk.)
020 $a9241209739$q(pbk.)
020 $a9789240689688
020 $a9240689680
035 $a(OCoLC)839866006$z(OCoLC)840430634$z(OCoLC)880216977$z(OCoLC)980553107$z(OCoLC)1055594189$z(OCoLC)1089783751
050 14 $aRA8$b.A25 no.973
060 4 $aQV 32.1 W628 no.973
082 04 $a616.86
110 2 $aWHO Expert Committee on Drug Dependence.
245 10 $aWHO Expert Committee on Drug Dependence :$bthirty-fifth report.
260 $aGeneva :$bWorld Health Organization,$c©2012.
300 $avi, 26 pages ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
490 1 $aWHO technical report series,$x0250-8737 ;$v973
500 $a"Thirty-fifth report."
500 $a"The WHO Expert Committee on Drug Dependence met in Hammamet, Tunisia from 4 to 8 June 2012"--Page 1.
504 $aIncludes bibliographical references.
505 0 $aMachine generated contents note: 1. Revision of guidelines -- 2. Work of international bodies concerned with controlled substances -- 3. Critical review of psychoactive substances -- 3.1. Substance recommended for change in scheduling -- y-Hydroxybutyric acid (GHB) -- 3.2. Other substance critically reviewed -- Ketamine (INN) -- 4. Pre-review of psychoactive substances -- 4.1. Dextromethorphan (pINN) -- 4.2. Tapentadol (INN) -- 4.3. Piperazines -- 4.3.1.N-Benzylpiperazine (BZP) -- 4.3.2.1-(3-Trifluoromethylphenyl) piperazine (TFMPP) -- 4.3.3.1-(3-Chlorophenyl) piperazine (mCPP) -- 4.3.4.1-(4-Methoxyphenyl) piperazine (MeOPP) -- 4.3.5.1-(3,4-Methylenedioxybenzyl) piperazine (MDBP) -- 4.4.y-Butyrolactone (GBL) -- 4.5.1,4-Butanediol (1,4-BD) -- 5. Issues identified for consideration at future ECDD meetings -- 6. Other matters -- 6.1. Use of terms -- 6.2. Use of pharmacovigilance data for the assessment of abuse and dependence potential -- 6.3. Balancing medical availability and prevention of abuse of medicines manufactured from controlled substances -- 6.4. Improving the process for substance evaluation.
540 $aCurrent Copyright Fee: GBP20.00$c0.$5Uk
650 0 $aPsychotropic drugs.
650 12 $aPsychotropic Drugs$xclassification.
650 22 $aDrug and Narcotic Control.
650 22 $aDrug Evaluation.
650 22 $aDrugs, Essential$xsupply & distribution.
650 22 $aInternational Cooperation.
650 7 $aPsychotropic drugs.$2fast$0(OCoLC)fst01081826
653 1 $aDrug dependence
653 1 $aWHO
710 2 $aWorld Health Organization.
776 08 $iOnline version:$aWHO Expert Committee on Drug Dependence.$tWHO Expert Committee on Drug Dependence.$dGeneva : World Health Organization, ©2012$w(OCoLC)1084210857
830 0 $aTechnical report series (World Health Organization) ;$v973.
856 41 $3Ebook Library$uhttp://public.eblib.com/choice/publicfullrecord.aspx?p=1222406
938 $aBrodart$bBROD$n107727897
938 $aYBP Library Services$bYANK$n10248414
938 $aYBP Library Services$bYANK$n10899431
029 0 $aNZ1$b14808782
029 1 $aAU@$b000050862699
029 1 $aUKMGB$b016324214
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 37 OTHER HOLDINGS